- In March 2024, AbbVie Inc., a key player in hormone therapies, announced the launch of an enhanced formulation of AndroGel, its flagship testosterone replacement therapy (TRT). The new version offers improved skin absorption and reduced application time, addressing patient concerns about convenience and consistency in hormone delivery. This development underlines AbbVie’s ongoing commitment to patient-centric innovations in the hypogonadism space and aims to maintain its leadership in the testosterone therapy segment
- In February 2024, Bayer AG received expanded European regulatory approval for Nebido, a long-acting injectable testosterone treatment, to include adolescent males diagnosed with delayed puberty due to hypogonadotropic hypogonadism. The extension supports Bayer’s strategic focus on increasing access to TRT among underserved patient populations, reflecting broader efforts to diversify therapeutic applications and strengthen its footprint in the hormonal treatment market
- In January 2024, Antares Pharma Inc. launched its new XYOSTED autoinjector device in select Asian markets, including Japan and South Korea. This once-weekly subcutaneous testosterone formulation is gaining attention for its ease of use and consistent dosing. The move marks the company’s entry into fast-growing APAC markets, where the prevalence of male hypogonadism is rising alongside awareness of hormone-related health conditions
- In December 2023, Besins Healthcare initiated a clinical trial for a novel oral testosterone undecanoate formulation intended to offer an alternative to injectable and transdermal options. The trial is being conducted in the U.S. and aims to evaluate long-term safety and efficacy. If approved, this formulation could represent a major breakthrough by providing a more user-friendly route of administration, potentially improving patient compliance
- In November 2023, Pfizer Inc. announced a partnership with an Indian pharmaceutical manufacturer to expand access to its Depo-Testosterone injectable treatment across emerging markets, including Southeast Asia and Africa. This collaboration aligns with Pfizer’s global access strategy and responds to increasing demand for reliable testosterone therapies in regions with growing male health awareness and limited access to specialty care
- In October 2023, Ferring Pharmaceuticals launched a digital companion app alongside its hCG injection therapy, aimed at patients with hypogonadotropic hypogonadism seeking fertility enhancement. The app helps users monitor treatment schedules, symptoms, and lab results while maintaining direct communication with clinicians. This tech-driven approach reflects the trend toward integrating digital health tools with traditional hormone therapies to boost engagement and adherence
